MELBOURNE, Australia – Adherium’s Smartinhaler is playing an integral role in a major European Union program to determine if mHealth systems can be used to help manage asthma.
“For such an eminent group of European Key Opinion Leaders to choose Smartinhaler to assess the impact of digital health solutions on asthma control and exacerbations is a major validation, not only of the role digital technologies can play in managing chronic respiratory diseases like asthma, but also in Smartinhaler as the leading solution in this space,” said Garth Sutherland, founder and CEO of Adherium.
The Smartinhaler is being used for the myAirCoach program, part of the EU’s Horizon 2020 Framework for Research and Innovation. The program is funded through the Horizon 2020 framework, which is the largest EU Research and Innovation program ever established.
Adherium’s Smartinhaler technology offers sensors for metered dose inhalers, dry powder inhalers and nebulizers, and works with a wireless platform for real-time data collection and reporting.
The company will supply a range of products to the myAirCoach program, including devices for inhaled medications manufactured by AstraZeneca and GSK.
The myAirCoach program, is coordinated by the Centre for Research and Technology Hellas (CERTH) in Thessaloniki, Greece, and supported by a group of asthma patients acting as advisors. It will explore whether home monitoring and mHealth systems can be used to predict asthma control and the occurrence of asthma exacerbations. The impact of the program is expected to become the basis for the widespread adoption of sensor-based self-management systems across the spectrum of respiratory diseases.
“Digital monitoring and interventions will become the chronic disease management standard of care,” said Sutherland. He said that his company already improves the lives of people with asthma and COPD through real-time delivery of invaluable insights that help with adherence and effectiveness of medical treatment they follow.